RLFTY (Relief Therapeutics Holding) Total Current Assets : $16.46 Mil (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Relief Therapeutics Holding Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Relief Therapeutics Holding's total current assets for the quarter that ended in Jun. 2024 was $16.46 Mil.

Relief Therapeutics Holding Total Current Assets Historical Data

The historical data trend for Relief Therapeutics Holding's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relief Therapeutics Holding Total Current Assets Chart

Relief Therapeutics Holding Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

0.27

52.74

59.69

24.24

21.17

Relief Therapeutics Holding Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Total Current Assets	Get a 7-Day Free Trial															36.06	24.24	18.17	21.17	16.46

Relief Therapeutics Holding Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Relief Therapeutics Holding's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	16.832	+	3.281	+	0.644	+	0.409
	=	21.17

Relief Therapeutics Holding's Total Current Assets for the quarter that ended in Jun. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	12.003	+	3.247	+	0.418	+	0.791
	=	16.46

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Relief Therapeutics Holding (OTCPK:RLFTY) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Relief Therapeutics Holding's Liquidation Value for the quarter that ended in Jun. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	12.003	-	24.227	+	0.75 * 1.079	+	0.5 * 0.418
=	-11.21

Relief Therapeutics Holding Total Current Assets Related Terms

Thank you for viewing the detailed overview of Relief Therapeutics Holding's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Relief Therapeutics Holding Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relief Therapeutics Holding SA (OTCPK:RLFTY) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

RLFTF:USA RLFz:UK 0QKQ:UK RLF:Switzerland

Address

Avenue de Secheron 15, Geneva, CHE, 1202

Website

https://www.relieftherapeutics.com

Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development such as RLF-TD011, and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast among others. Geographically the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.